ASUNAPREVIR (ASV; BMS-650032), AN NS3 PROTEASE INHIBITOR, IN COMBINATION WITH PEGINTERFERON AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION

被引：0

作者：

Bronowicki, J-P ^{[1
]}

Pol, S. ^{[2
]}

Thuluvath, P. ^{[3
]}

Larrey, D. ^{[4
]}

Martorell, C. T. ^{[5
]}

Rustgi, V. K. ^{[6
]}

Morris, D. W. ^{[7
]}

Younes, Z. ^{[8
]}

Fried, M. W. ^{[9
]}

Bourliere, M. ^{[10
]}

Hezode, C. ^{[11
]}

Reddy, R. ^{[12
]}

Massoud, O. ^{[13
]}

Abrams, G. A. ^{[14
]}

Ratziu, V. ^{[15
]}

He, B. ^{[16
]}

Eley, T. ^{[16
]}

Ahmad, A. ^{[16
]}

Thiry, A. ^{[16
]}

Llamoso, C. ^{[16
]}

Mendez, P. ^{[16
]}

Hughes, E. ^{[16
]}

机构：

[1] Hop Adultes Brabois, Serv Hepatogastroenterol, Vandoeuvre Les Nancy, France

[2] Hop Cochin, Serv Hepatol Adulte, F-75674 Paris, France

[3] Mercy Med Ctr, Baltimore, MD USA

[4] Hop St Eloi, Serv Hepatogastroenterol & Transplantat, Montpellier, France

[5] Res Inst, Springfield, MA USA

[6] Metropolitan Res, Fairfax, VA USA

[7] Healthcare Res Consultants, Tulsa, OK USA

[8] Gastro One, Germantown, TN USA

[9] Univ N Carolina, Sch Med, Div Gastroenterol & Hepatol, Chapel Hill, NC USA

[10] Hop St Joseph, Serv Hepatogastroenterol, Marseille, France

[11] CHU Henri Mondor, Serv Hepatogastroenterol, F-94010 Creteil, France

[12] Hosp Univ Penn, Philadelphia, PA 19104 USA

[13] Univ Alabama Birmingham, Birmingham, AL USA

[14] Alabama Liver & Digest Specialists, Montgomery, AL USA

[15] Grp Hosp Pitie Salpetriere, Serv Hepatogastroenterol, F-75634 Paris, France

[16] Bristol Myers Squibb Co, Clin Res & Dev, Princeton, NJ USA

来源：

JOURNAL OF HEPATOLOGY | 2012年 / 56卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1096

引用

下载

页码：S431 / S432

页数：2

共 50 条

[1] BMS-650032, AN NS3 INHIBITOR, IN COMBINATION WITH PEGINTERFERON ALPHA-2A AND RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION
Bronowicki, J. -P.
Pol, S.
Thuluvath, P. J.
Larrey, D.
Martorell, C. T.
Rustgi, V. K.
Morris, D. W.
Younes, Z.
Fried, M. W.
Bourliere, M.
Hezode, C.
Massoud, O.
Abrams, G. A.
Ratziu, V.
Thiry, A.
Llamoso, C.
Hughes, E. A.
Hindes, R. G.
JOURNAL OF HEPATOLOGY, 2011, 54 : S472 - S472
[2] The Discovery of Asunaprevir (BMS-650032), An Orally Efficacious NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection
Scola, Paul M.
Sun, Li-Qiang
Wang, Alan Xiangdong
Chen, Jie
Sin, Ny
Venables, Brian L.
Sit, Sing-Yuen
Chen, Yan
Cocuzza, Anthony
Bilder, Donna M.
D'Andrea, Stanley V.
Zheng, Barbara
Hewawasam, Piyasena
Tu, Yong
Friborg, Jacques
Falk, Paul
Hernandez, Dennis
Levine, Steven
Chen, Chaoqun
Yu, Fei
Sheaffer, Amy K.
Zhai, Guangzhi
Barry, Diana
Knipe, Jay O.
Han, Yong-Hae
Schartman, Richard
Donoso, Maria
Mosure, Kathy
Sinz, Michael W.
Zvyaga, Tatyana
Good, Andrew C.
Rajamani, Ramkumar
Kish, Kevin
Tredup, Jeffrey
Klei, Herbert E.
Gao, Qi
Mueller, Luciano
Colonno, Richard J.
Grasela, Dennis M.
Adams, Stephen P.
Loy, James
Levesque, Paul C.
Sun, Huabin
Shi, Hong
Sun, Lucy
Warner, William
Li, Danshi
Zhu, Jialong
Meanwell, Nicholas A.
McPhee, Fiona
JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (05) : 1730 - 1752
[3] Pharmacokinetics of the NS3 Protease Inhibitor, Asunaprevir (ASV, BMS-650032), in Phase I Studies in Subjects With or Without Chronic Hepatitis C
Eley, Timothy
He, Bing
Huang, Shu-Pang
Li, Wenying
Pasquinelli, Claudio
Rodrigues, A. David
Grasela, Dennis M.
Bertz, Richard J.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2013, 2 (04): : 316 - 327
[4] Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)
McPhee, Fiona
Sheaffer, Amy K.
Friborg, Jacques
Hernandez, Dennis
Falk, Paul
Zhai, Guangzhi
Levine, Steven
Chaniewski, Susan
Yu, Fei
Barry, Diana
Chen, Chaoqun
Lee, Min S.
Mosure, Kathy
Sun, Li-Qiang
Sinz, Michael
Meanwell, Nicholas A.
Colonno, Richard J.
Knipe, Jay
Scola, Paul
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (10) : 5387 - 5396
[5] Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS-650032), a Potent Hepatitis C Virus NS3 Protease Inhibitor
Mosure, Kathleen W.
Knipe, Jay O.
Browning, Marc
Arora, Vinod
Shu, Yue-Zhong
Phillip, Thomas
Mcphee, Fiona
Scola, Paul
Balakrishnan, Anand
Soars, Matthew G.
Santone, Kenneth
Sinz, Michael
JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 104 (09) : 2813 - 2823
[6] DUAL ORAL THERAPY WITH THE NS5A INHIBITOR DACLATASVIR (BMS-790052) AND NS3 PROTEASE INHIBITOR ASUNAPREVIR (BMS-650032) IN HCV GENOTYPE 1B-INFECTED NULL RESPONDERS OR INELIGIBLE/INTOLERANT TO PEGINTERFERON/RIBAVIRIN
Suzuki, F.
Ikeda, K.
Toyota, J.
Karino, Y.
Ohmura, T.
Chayama, K.
Takahashi, S.
Kawakami, Y.
Ishikawa, H.
Watanabe, H.
Hu, W.
McPhee, F.
Hughes, E.
Kumada, H.
JOURNAL OF HEPATOLOGY, 2012, 56 : S7 - S8
[7] CHARACTERIZATION OF VIROLOGIC ESCAPE IN HCV GENOTYPE 1 NULL RESPONDERS RECEIVING A COMBINATION OF THE NS3 PROTEASE INHIBITOR BMS-650032 AND NS5A INHIBITOR BMS-790052
McPhee, F.
Hernandez, D.
Yu, F.
Ueland, J.
Wang, C.
Huang, H.
Gardiner, D.
Fridell, R.
Gao, M.
JOURNAL OF HEPATOLOGY, 2011, 54 : S28 - S29
[8] SAFETY AND ANTIVIRAL ACTIVITY OF BI201335, A NEW HCV NS3 PROTEASE INHIBITOR, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE-1 INFECTION GIVEN AS MONOTHERAPY AND IN COMBINATION WITH PEGINTERFERON ALFA 2A (P) AND RIBAVIRIN (R)
Manns, Michael P.
Bourliere, Marc
Benhamou, Yves
Pol, Stanislas
Bonacini, Maurizio
Berg, Thomas
Trepo, Christian
Wright, David
Steinmann, Gerhard
Huang, David B.
Mikl, Jaromir
Kukolj, George
Stern, Jerry O.
HEPATOLOGY, 2008, 48 (04) : 1133A - 1133A
[9] Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
Kwo, Paul Y.
Lawitz, Eric J.
McCone, Jonathan
Schiff, Eugene R.
Vierling, John M.
Pound, David
Davis, Mitchell N.
Galati, Joseph S.
Gordon, Stuart C.
Ravendhran, Natarajan
Rossaro, Lorenzo
Anderson, Frank H.
Jacobson, Ira M.
Rubin, Raymond
Koury, Kenneth
Pedicone, Lisa D.
Brass, Clifford A.
Chaudhri, Eirum
Albrecht, Janice K.
LANCET, 2010, 376 (9742): : 705 - 716
[10] A PHASE 2A STUDY OF BMS-791325, AN NS5B POLYMERASE INHIBITOR, WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION
Tatum, H.
Thuluvath, P.
Lawitz, E.
Martorell, C. T.
Demicco, M.
Cohen, S.
Rustgi, V.
Ravendhran, N.
Ghalib, R.
Hanson, J.
Zamparo, J.
Yang, R.
Hughes, E.
Cooney, E.
JOURNAL OF HEPATOLOGY, 2012, 56 : S460 - S460

← 1 2 3 4 5 →